IPHYF Stock Price, Chart, Stats & News

Innate Pharma S.A.
Save
Innate Pharma S.A. (IPHYF) does not currently pay a dividend.
154.94M
Market cap
–
Current P/E
11.42x
Forward P/E
IPHYF chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Innate Pharma S. A., a biotechnology firm based in Marseille, France, operates globally, focusing on the discovery, advancement, and commercialization of innovative antibody-based therapies, primarily targeting various oncological conditions. The company's clinical pipeline includes several promising candidates: Lacutamab (IPH4102): An anti-KIR3DL2 antibody currently undergoing Phase II clinical evaluation for cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome.
Similar securities
Based on sector and market capitalization
Report issue





